Patents by Inventor Kathrin Ulrike Tissot-Daguette

Kathrin Ulrike Tissot-Daguette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CKIT antibody drug conjugates
    Patent number: 11833215
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: December 5, 2023
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING EPO
    Publication number: 20210355206
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Application
    Filed: July 22, 2021
    Publication date: November 18, 2021
    Inventors: Joy Gispati GHOSH, Michael ROGUSKA, Mark Anthony RUTZ, Igor SPLAWSKI, Kathrin Ulrike TISSOT-DAGUETTE
  • CKIT ANTIBODY DRUG CONJUGATES
    Publication number: 20200405875
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: June 4, 2020
    Publication date: December 31, 2020
    Inventors: Tinya ABRAMS, Steven Bruce COHEN, Dylan DANIEL, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Thomas HUBER, William Mallet, Matthew John MEYER, Weijia OU, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
  • CKIT antibody drug conjugates
    Patent number: 10786578
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: September 29, 2020
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20200129632
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: December 9, 2019
    Publication date: April 30, 2020
    Inventors: Tinya ABRAMS, Steven COHEN, Christie P. FANTON, Catrin FINNER, Thomas HUBER, Kathy MILLER, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING EPO
    Publication number: 20200048341
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Application
    Filed: July 3, 2019
    Publication date: February 13, 2020
    Inventors: Joy GHOSH, Michael ROGUSKA, Mark Anthony RUTZ, Igor SPLAWSKI, Kathrin Ulrike TISSOT-DAGUETTE
  • Compositions and methods for antibodies targeting EPO
    Patent number: 10385127
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: August 20, 2019
    Assignee: NOVARTIS AG
    Inventors: Joy Ghosh, Mark Anthony Rutz, Kathrin Ulrike Tissot-Daguette, Igor Splawski, Michael Roguska
  • ANTIBODIES TARGETING BONE MORPHOGENETIC PROTEIN 9 (BMP9) AND METHODS THEREFOR
    Publication number: 20190153084
    Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof which bind human BMP9 and compositions and methods of use thereof.
    Type: Application
    Filed: July 5, 2018
    Publication date: May 23, 2019
    Applicant: NOVARTIS AG
    Inventors: Zijun Chen, Sujun Deng, Yun He, Dagang Huang, Markus Kugler, Qian Li, Chris Xiangyang Lu, Xiao Luo, Yongqiang Shan, Kathrin Ulrike Tissot-Daguette, Jing Wu
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING EPO
    Publication number: 20190135913
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Application
    Filed: September 13, 2018
    Publication date: May 9, 2019
    Applicant: NOVARTIS AG
    Inventors: Joy GHOSH, Mark Anthony RUTZ, Kathrin Ulrike TISSOT-DAGUETTE, Igor SPLAWSKI, Michael ROGUSKA
  • Antibody drug conjugates
    Patent number: 10117953
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: November 6, 2018
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
  • Compositions and methods for antibodies targeting Epo
    Patent number: 10106605
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: October 23, 2018
    Assignee: NOVARTIS AG
    Inventors: Joy Ghosh, Mark Anthony Rutz, Kathrin Ulrike Tissot-Daguette, Igor Splawski, Michael Roguska
  • Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
    Patent number: 10047155
    Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof which bind human BMP9 and compositions and methods of use thereof.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 14, 2018
    Assignee: NOVARTIS AG
    Inventors: Zijun Chen, Sujun Deng, Yun He, Dagang Huang, Markus Kugler, Qian Li, Chris Xiangyang Lu, Xiao Luo, Yongqiang Shan, Kathrin Ulrike Tissot-Daguette, Jing Wu
  • CKIT ANTIBODY DRUG CONJUGATES
    Publication number: 20180193475
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: July 27, 2015
    Publication date: July 12, 2018
    Inventors: Tinya ABRAMS, Steven Bruce COHEN, Dylan DANIEL, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Thomas HUBER, William MALLET, Matthew John MEYER, Weijia OU, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20180125996
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: August 30, 2017
    Publication date: May 10, 2018
    Inventors: Tinya ABRAMS, Steven COHEN, Christie P. FANTON, Catrin FINNER, Thomas HUBER, Kathy MILLER, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
  • cKIT antibody drug conjugates
    Patent number: 9789203
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 17, 2017
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Cohen, Christie P. Fanton, Catrin Finner, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20170035905
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: October 3, 2016
    Publication date: February 9, 2017
    Applicant: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
  • ANTIBODIES TARGETING BONE MORPHOGENETIC PROTEIN 9 (BMP9) AND METHODS THEREFOR
    Publication number: 20160355583
    Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof which bind human BMP9 and compositions and methods of use thereof.
    Type: Application
    Filed: May 26, 2016
    Publication date: December 8, 2016
    Applicant: NOVARTIS AG
    Inventors: Zijun CHEN, Sujun DENG, Yun HE, Dagang HUANG, Markus KUGLER, Qian LI, Chris Xiangyang LU, Xiao LUO, Yongqiang SHAN, Kathrin Ulrike TISSOT-DAGUETTE, Jing WU
  • Antibody drug conjugates
    Patent number: 9498543
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: November 22, 2016
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING EPO
    Publication number: 20160280783
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Application
    Filed: June 13, 2016
    Publication date: September 29, 2016
    Applicant: Novartis AG
    Inventors: Joy GHOSH, Mark Anthony RUTZ, Kathrin Ulrike TISSOT-DAGUETTE, Igor SPLAWSKI, Michael ROGUSKA
  • Compositions and methods for antibodies targeting EPO
    Patent number: 9365646
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: June 14, 2016
    Assignee: NOVARTIS AG
    Inventors: Joy Ghosh, Mark Anthony Rutz, Kathrin Ulrike Tissot-Daguette, Igor Splawski, Michael Roguska